伤口导向灌注在Rheocarna血液净化治疗难治性慢性肢体威胁性缺血血管外科登记中的研究
本研究基于两中心53例难治性慢性肢体威胁性缺血肢体的回顾性单臂登记,描述Rheocarna血液净化在血管外科路径中的使用,并分析伤口导向灌注参数与愈合及复发的关系。结果显示完全伤口愈合40例(75.5%),6和12个月累积愈合估计分别为81%和86%,12个月保肢率85.9%。可视化流向伤口床(VFW)与更高愈合及更少额外小截肢相关,持续足部流入(SPI)与更高无复发伤口稳定性相关。
要点
- Rheocarna治疗难治性CLTI肢体完全伤口愈合率75.5%,12个月保肢率85.9%。
- VFW与更高愈合及更少额外小截肢相关,SPI与更高无复发伤口稳定性相关。
- 治疗期间纤维蛋白原下降,白蛋白和C反应蛋白保持稳定。
核心结论
- 在该血管外科路径中,伤口导向灌注参数VFW和SPI是结局的主要相关因素,可能优化Rheocarna候选者选择。
研究设计与样本
- 回顾性描述性单臂两中心登记,纳入2021至2025年接受Rheocarna治疗的53例CLTI肢体,无对照组,所有肢体接受综合保肢治疗。
主要发现
- 完全伤口愈合40例(75.5%),6和12个月累积愈合估计分别为81%和86%。
- 12个月保肢率为85.9%。
- VFW与更高愈合和更少额外小截肢相关;SPI与更高无复发伤口稳定性相关。
- 治疗期间纤维蛋白原下降,白蛋白和C反应蛋白保持稳定。
关键数值与推荐
- 膝下血运重建包括开放旁路13例和血管内治疗21例,19例肢体不适合血运重建。
- 共同股动脉内膜剥脱术视为流入道重建;内膜剥脱加浅股动脉治疗归类为血管内治疗。
临床怎么用
- 在血管外科路径中,可依据伤口导向灌注参数VFW和SPI评估Rheocarna治疗候选者,VFW关注初始愈合,SPI关注无复发 durability。
局限性
- 回顾性单臂描述性登记,无对照组,需前瞻性比较研究确立疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Rheocarna® is a selective low-density lipoprotein and fibrinogen apheresis device introduced in Japan as an adjunctive option for chronic limb-threatening ischemia (CLTI). Real-world data in treatment-refractory limbs managed within a vascular-surgery pathway are scarce. We assembled a two-center registry to describe its use and examine which wound-directed perfusion parameters track with healing and recurrence. METHODS: We retrospectively analyzed all 53 CLTI limbs receiving Rheocarna at two vascular-surgery-led centers (2021-2025). This descriptive, single-arm registry had no comparator; all limbs received comprehensive limb-salvage care. Perfusion was characterized using wound-oriented angiography, including visualized flow to the wound bed (VFW) and sustained pedal inflow (SPI). Common femoral endarterectomy was regarded as inflow reconstruction; limbs treated by endarterectomy plus superficial femoral artery treatment were classified as endovascular therapy. Infrainguinal revascularization comprised open bypass (n = 13) and endovascular therapy (n = 21); 19 limbs were unsuitable for revascularization. Outcomes were estimated by Kaplan-Meier analysis, with VFW and SPI explored using penalized Cox models. RESULTS: Complete wound healing occurred in 40 limbs (75.5%), with cumulative estimates of 81% and 86% at 6 and 12 months. Limb salvage at 12 months was 85.9%. VFW was associated with higher healing and fewer additional minor amputations; SPI with greater recurrence-free wound stability. Fibrinogen fell during therapy while albumin and C-reactive protein were stable. CONCLUSION: Within this pathway, wound-directed perfusion, VFW for initial healing, and SPI for recurrence-free durability were the dominant correlates of outcome and may refine candidate selection for Rheocarna. Prospective comparative studies are required to establish efficacy.
引用
- Tamaru Y, Kikuchi S, Hashimoto Y, et al. Wound-Directed Perfusion in a Vascular Surgery Registry of Rheocarna Apheresis for Treatment-Refractory Chronic Limb-Threatening Ischemia: Visualized Flow to the Wound Bed and Sustained Pedal Inflow as Determinants of Healing and Recurrence. Ann Vasc Surg. 2026. PMID: 42456967. doi:10.1016/j.avsg.2026.07.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。